Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib

被引：62
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Mussolin, Lara [2 ]
Brugieres, Laurence [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Univ Padua, Padua, Italy
[3] Gustave Roussy Canc Campus, Villejuif, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 01期
关键词：
LARGE-CELL LYMPHOMA;
D O I：
10.1056/NEJMc1511045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [21] Proof of Principle for Crizotinib in Anaplastic Lymphoma Kinase-Positive Malignancies Was Achieved in ALK-Positive Nonclinical Models
    Christensen, James G.
    MOLECULAR CANCER THERAPEUTICS, 2011, 10 (11) : 2024 - 2024
  • [22] Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Thibault, Constance
    Teixeira, Luis
    ONCOLOGIE, 2013, 15 (09) : 494 - 495
  • [23] EFFICACY AND TOXICITY OF CRIZOTINIB FOR PATIENTS WITH ALK-POSITIVE ADVANCED NSCLC
    Asao, T.
    Honma, Y.
    Suina, K.
    Muraki, K.
    Shukuya, T.
    Ohashi, R.
    Koyama, R.
    Shimada, N.
    Sakuraba, S.
    Takahashi, K.
    ANNALS OF ONCOLOGY, 2013, 24
  • [24] A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
    Dikopf, Alana
    Wood, Kevin
    Salgia, Ravi
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (03) : 485 - 493
  • [25] Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
    Cui, Shaohua
    Zhao, Yizhuo
    Gu, Aiqin
    Ge, Xiaoxiao
    Song, Yanyan
    Zhang, Wei
    Lou, Yuqing
    Dong, Lili
    Han, Baohui
    Jiang, Liyan
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S412 - S412
  • [26] First-Line Crizotinib in ALK-Positive Lung Cancer
    Alkan, Ali
    Koksoy, Elif B.
    Utkan, Gungor
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 781 - 782
  • [27] Renal Effects of Crizotinib in Patients With ALK-Positive Advanced NSCLC
    Camidge, D. Ross
    Kim, Elizabeth E.
    Usari, Tiziana
    Polli, Anna
    Lewis, Iona
    Wilner, Keith D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1077 - 1085
  • [28] Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics
    Meurillon, Roxane
    Leruste, Amaury
    BULLETIN DU CANCER, 2023, 110 (03) : 250 - 251
  • [29] Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC
    Lei, Yuan-Yuan
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhong, Wen-Zhao
    Zhou, Qing
    Tu, Hai-Yan
    Tian, Hong-Xia
    Guo, Wei-Bang
    Yang, Lu-Lu
    Yan, Hong-Hong
    Chen, Hua-Jun
    Xie, Zhi
    Su, Jian
    Han, Jie-Fei
    Wu, Yi-Long
    CLINICAL LUNG CANCER, 2016, 17 (03) : 223 - 231
  • [30] Everolimus in Combination with Crizotinib Synergistically Inhibits the Growth of ALK-Positive Anaplastic Large Cell Lymphoma Cells
    Xu, Wendan
    Kim, Ji-Won
    Lee, Junglim
    Kim, Hyo Jung
    Yoon, Hwi-Joong
    Yoon, Sung-Soo
    BLOOD, 2014, 124 (21)
12345